Christopher Gottschalk, MD, FAHS
Professor; Chief, Division of General Neurology, Neurology; Director, Fellowship Program, Headache & Facial Pain Center
Research & Publications
Biography
News
Research Summary
We are actively involved in Phase 2 and 3 clinical trials for the treatment of Migraine, Cluster headache, and related conditions.
Coauthors
Research Interests
Brain Mapping; Cluster Headache; Migraine Disorders; Neurochemistry; Cortical Spreading Depression; Trigeminal Neuralgia; Headache Disorders, Primary; Headache Disorders, Secondary; Trigeminal Autonomic Cephalalgias
Public Health Interests
Chronic Diseases; Health Care Management; Substance Use, Addiction; Child/Adolescent Health; Health Equity, Disparities, Social Determinants and Justice
Selected Publications
- Cognitive function and cerebral perfusion during cocaine abstinence.Gottschalk C, Beauvais J, Hart R, Kosten T. Cognitive function and cerebral perfusion during cocaine abstinence. The American Journal Of Psychiatry 2001, 158: 540-5. PMID: 11282686, DOI: 10.1176/appi.ajp.158.4.540.
- Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking.Staley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O'Malley S, Baldwin R, Jatlow P, Verhoeff NP, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking. Archives Of General Psychiatry 2005, 62: 877-88. PMID: 16061765, DOI: 10.1001/archpsyc.62.8.877.
- Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey.Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-81. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.
- Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins.Schaefer SM, Gottschalk CH, Jabbari B. Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins 2015, 7: 2615-28. PMID: 26184313, PMCID: PMC4516932, DOI: 10.3390/toxins7072615.
- Telcagepant--almost gone, but not to be forgotten (invited editorial related to Ho et al., 2015).Gottschalk PC. Telcagepant--almost gone, but not to be forgotten (invited editorial related to Ho et al., 2015). Cephalalgia : An International Journal Of Headache 2016, 36: 103-5. PMID: 25944815, DOI: 10.1177/0333102415584311.
- Beta-Blockers for Migraine Prevention: a Review Article.Danesh A, Gottschalk PCH. Beta-Blockers for Migraine Prevention: a Review Article. Current Treatment Options In Neurology 2019, 21: 20. PMID: 30903383, DOI: 10.1007/s11940-019-0556-3.
- Cognitive Biases & Errors in Headache Medicine.Gottschalk CH. Cognitive Biases & Errors in Headache Medicine. Headache 2019, 59: 1863-1870. PMID: 31680238, DOI: 10.1111/head.13686.
- Functional magnetic resonance imaging of cocaine craving.Wexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC. Functional magnetic resonance imaging of cocaine craving. The American Journal Of Psychiatry 2001, 158: 86-95. PMID: 11136638, DOI: 10.1176/appi.ajp.158.1.86.
- The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.Schwedt TJ, Digre K, Tepper SJ, Spare NM, Ailani J, Birlea M, Burish M, Mechtler L, Gottschalk C, Quinn AM, McGillicuddy L, Bance L, Dumkrieger G, Chong CD, Dodick DW. The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. Headache 2020, 60: 337-347. PMID: 31755111, DOI: 10.1111/head.13688.
- Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia.Dong W, Jin SC, Allocco A, Zeng X, Sheth AH, Panchagnula S, Castonguay A, Lorenzo LÉ, Islam B, Brindle G, Bachand K, Hu J, Sularz A, Gaillard J, Choi J, Dunbar A, Nelson-Williams C, Kiziltug E, Furey CG, Conine S, Duy PQ, Kundishora AJ, Loring E, Li B, Lu Q, Zhou G, Liu W, Li X, Sierant MC, Mane S, Castaldi C, López-Giráldez F, Knight JR, Sekula RF, Simard JM, Eskandar EN, Gottschalk C, Moliterno J, Günel M, Gerrard JL, Dib-Hajj S, Waxman SG, Barker FG, Alper SL, Chahine M, Haider S, De Koninck Y, Lifton RP, Kahle KT. Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia. IScience 2020, 23: 101552. PMID: 33083721, PMCID: PMC7554653, DOI: 10.1016/j.isci.2020.101552.
- Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.
- Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza DC. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics : The Journal Of The American Society For Experimental NeuroTherapeutics 2021, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.
- Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population.Torabi SJ, Kasle DA, Savoca EL, Gottschalk CH, Manes RP. Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache 2021, 61: 373-384. PMID: 33337542, DOI: 10.1111/head.14040.